Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | GAA | P10253 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | S100B | P04271 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533605 | 0.98 | ALDH1A1 (0.56) | ALDH1A1GAAMEN1MAPTKMT2A | |
| SCHEMBL11439640 | 0.90 | ALDH1A1 (0.56) | ALDH1A1GAAMEN1MAPTKMT2A | |
| SCHEMBL28854051 | 0.88 | ALDH1A1 (0.52) | ALDH1A1GAAMEN1MAPTKMT2A | |
| SCHEMBL5564547 | 0.82 | ALDH1A1 (0.46) | ALDH1A1GAAMEN1MAPTKMT2A | |
| SCHEMBL19170711 | 0.81 | ALDH1A1 (0.62) | ALDH1A1GAAMEN1MAPTKMT2A | |
| SCHEMBL23759791 | 0.79 | TSHR (0.55) | ALDH1A1GAAMEN1MAPTKMT2A | |
| SCHEMBL8324237 | 0.75 | ALDH1A1 (0.53) | ALDH1A1GAAMEN1MAPTKMT2A | |
| SCHEMBL10126834 | 0.74 | ADRA2C (0.52) | ALDH1A1GAAMEN1MAPTKMT2A | |
| SCHEMBL241271 | 0.74 | ALDH1A1 (0.93) | ALDH1A1GAAMEN1MAPTKMT2A | |
| SCHEMBL19136007 | 0.74 | ALDH1A1 (0.67) | ALDH1A1GAAMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415760-A2 | CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7579340-B2 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | PFIZER INC (US) | 2009-08-25 | — | — | US | disclosed |
| US-7319111-B2 | Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070293503-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7288538-B2 | Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-03 | — | — | US | disclosed |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| US-4394156-A | Novel N-phenyl-substituted N-heterocyclic compounds, their preparation and use in agents for regulating plant growth | CIBA-GEIGY CORPORATION (US) | 1983-07-19 | — | — | US | disclosed |
| US-4294606-A | HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1981-10-13 | — | — | US | disclosed |
| US-4208202-A | HERBICIDES | CIBA-GEIGY CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | ALDH1A1 3281/4885GAA 2037/4885MEN1 3986/4885 |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | ALDH1A1 3281/4885GAA 2037/4885MEN1 3986/4885 |
| US-20070293503-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | ALDH1A1 3281/4885GAA 2037/4885MEN1 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.